Ovarian cancer organoid biobank
Ovarian cancer (OC) is a heterogeneous disease usually diagnosed at a late stage. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of OC are limited and hard to establish. We present a novel protocol that enables efficient derivation and long-term expansion of OC organoids. Utilizing this protocol, we have established 56 organoid lines from 32 patients, representing the spectrum of ovarian neoplasms, including non-malignant borderline tumors, as well as mucinous, clear-cell, endometrioid, low- and high-grade serous carcinomas. OC organoids recapitulate histological and genomic features of the pertinent lesion from which they were derived, illustrating intra- and inter-patient heterogeneity, and can be genetically modified. We show that OC organoids can be used for drug screening assays and capture different tumor subtype responses to the gold standard platinum-based chemotherapy, including acquisition of chemoresistance in recurrent disease. Finally, OC organoids can be xenografted, enabling in vivo drug sensitivity assays. Taken together, this demonstrates their potential application for research and personalized medicine.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001004387 | HiSeq X Ten | 111 | |
EGAD00001004509 | NextSeq 500 | 50 | |
EGAD00001005476 | MinION | 2 | |
EGAD00001005707 | HiSeq X Ten | 23 |
Publications | Citations |
---|---|
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Nat Med 25: 2019 838-849 |
386 |
Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients.
Genome Med 13: 2021 86 |
13 |
Primary human organoids models: Current progress and key milestones.
Front Bioeng Biotechnol 11: 2023 1058970 |
10 |
Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models.
J Natl Cancer Cent 2: 2022 263-276 |
10 |